Fundraising FoxBioluminescence Ventures — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Board seatKouki Harasaki· per SEC Form D
Co-investors5AM VenturesAju IB InvestmentCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+10 more
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Board seatKouki Harasaki· per SEC Form D · $290M raise · filed Sep 2023
Co-investorsAju IB InvestmentEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
SURGE Therapeutics, Inc.Nido Biosciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.